Shang-Fan Yu Selected Research

Immunoconjugates (Immunoconjugate)

1/2024	The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
3/2022	A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides.
1/2021	An Anti-CD22-seco-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models.
1/2021	Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
1/2021	Calicheamicin Antibody-Drug Conjugates with Improved Properties.
10/2019	Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer.
10/2019	Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
1/2019	An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.
10/2018	Characterization of in vivo biotransformations for trastuzumab emtansine by high-resolution accurate-mass mass spectrometry.
1/2018	Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shang-Fan Yu Research Topics

Disease

37	Neoplasms (Cancer) 01/2024 - 01/2003
10	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2023 - 07/2007
5	Prostatic Neoplasms (Prostate Cancer) 10/2019 - 01/2003
4	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2003
3	Breast Neoplasms (Breast Cancer) 01/2024 - 01/2016
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2023 - 03/2011
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 01/2019
2	Multiple Myeloma 01/2019 - 10/2012
1	Hematologic Diseases (Blood Diseases) 10/2023
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2023
1	Leukemia 01/2021
1	Hodgkin Disease (Hodgkin's Disease) 01/2021
1	Hematologic Neoplasms (Hematological Malignancy) 01/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021
1	Body Weight (Weight, Body) 12/2016
1	Colonic Neoplasms (Colon Cancer) 11/2015
1	AIDS-Related Complex (ARC) 01/2015
1	Arthrogryposis renal dysfunction cholestasis syndrome 01/2015
1	Lymphoma (Lymphomas) 07/2013
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 10/2009
1	Autoimmune Diseases (Autoimmune Disease) 10/2009
1	Carcinoma (Carcinomatosis) 01/2003

Drug/Important Bio-Agent (IBA)

23	Immunoconjugates (Immunoconjugate)IBA 01/2024 - 07/2007
8	AntibodiesIBA 01/2024 - 10/2009
7	AntigensIBA 01/2022 - 07/2011
4	auristatinIBA 01/2021 - 07/2013
4	Monoclonal AntibodiesIBA 10/2019 - 03/2011
3	Rituximab (Mabthera)FDA Link 01/2023 - 07/2011
3	Proteins (Proteins, Gene)FDA Link 01/2023 - 09/2012
3	polatuzumab vedotinIBA 01/2023 - 10/2019
3	pinatuzumab vedotinIBA 01/2021 - 07/2013
3	monomethyl auristatin EIBA 01/2021 - 05/2016
3	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 01/2016
3	LuciferasesIBA 05/2004 - 01/2003
2	Ado-Trastuzumab EmtansineIBA 01/2024 - 10/2018
2	Bispecific AntibodiesIBA 01/2022 - 10/2021
2	Surface Antigens (Surface Antigen)IBA 10/2021 - 10/2009
2	A-Form DNA (A-DNA)IBA 10/2020 - 12/2016
2	Proteoglycans (Proteoglycan)IBA 10/2019 - 09/2012
2	maleimideIBA 10/2018 - 01/2012
2	DisulfidesIBA 01/2017 - 12/2016
2	Sulfhydryl Compounds (Thiols)IBA 01/2016 - 01/2012
2	dacetuzumabIBA 07/2011 - 03/2011
1	DHES0815AIBA 01/2024
1	trastuzumab deruxtecanIBA 01/2024
1	venetoclaxIBA 01/2023
1	obinutuzumabIBA 01/2023
1	snake venom protein C activatorIBA 11/2022
1	Sucrose (Saccharose)IBA 11/2022
1	LigandsIBA 11/2022
1	Brentuximab VedotinIBA 01/2021
1	Gemtuzumab (Mylotarg)FDA Link 01/2021
1	Inotuzumab OzogamicinIBA 01/2021
1	CalicheamicinsIBA 01/2021
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2021
1	Immunoglobulin G (IgG)IBA 01/2020
1	Phosphotransferases (Kinase)IBA 01/2019
1	EstersIBA 10/2018
1	Glutathione (Reduced Glutathione)IBA 10/2018
1	maytansinolIBA 10/2018
1	Cysteine (L-Cysteine)FDA Link 10/2018
1	Peptide Hydrolases (Proteases)FDA Link 01/2018
1	Cytotoxins (Cytolysins)IBA 10/2017
1	Alkylating AgentsIBA 12/2016
1	DNA AdductsIBA 12/2016
1	pyrrolo(2,1-c)(1,4)benzodiazepineIBA 12/2016
1	Trastuzumab (Herceptin)FDA Link 01/2016
1	AnthracyclinesIBA 07/2015
1	3'- deamino- 3'',4'- anhydro- (2''- methoxy- 3''- oxy- 4''- morpholinyl)doxorubicinIBA 07/2015
1	Small Interfering RNA (siRNA)IBA 01/2015
1	Bortezomib (Velcade)FDA Link 10/2012
1	Lenalidomide (CC 5013)FDA Link 10/2012
1	Epidermal Growth Factor (EGF)IBA 09/2012
1	FollistatinIBA 09/2012
1	succinimideIBA 01/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2009
1	CD19 AntigensIBA 03/2009
1	Drug CombinationsIBA 03/2009
1	Hormones (Hormone)IBA 05/2004
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2003
1	Fluorouracil (Carac)FDA LinkGeneric 01/2003

Therapy/Procedure

12	Therapeutics 10/2023 - 10/2009
2	Drug Therapy (Chemotherapy) 01/2003 - 01/2003
1	Transcranial Direct Current Stimulation 01/2017
1	Castration 05/2016
1	Combination Drug Therapy (Combination Chemotherapy) 07/2013
1	Aftercare (After-Treatment) 01/2003